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Carcinoembryonic antigen (CEA) is a tumor marker that 
belongs to a family of closely related molecules with variable 
expression patterns. We have developed sets of oligonucleotide 
primers for the specific amplification of transcripts from individ- 
ual CEA-family members using the reverse transcriptare/ 
polymerase chain reaction (RT/PCR). Specific primer sets were 
designed for CEA, non-specific cross-reacting antigen (NCA), 
biliary glycoprotein (BGP), carcinoembryonic antigen gene- 
family members I, 6 and 7 (CGM I, CGM6 and CGM'I), and one 
set for all pregnancy-specific glycoprotein (PSG) transcripts. 
Primers were first tested for their specificity against individual 
cDNA clones and product-hybridization with internal, transcript- 
specific oligonucleotides. Total RNA from I 2  brain and 63 
gynecological tumors were then tested for expression of CEA- 
related transcripts. None were found in tumors located in the 
brain, including various mesenchymal and neuro-epithelial tu- 
mors. CEA and NCA transcripts were, however, present in an 
adenocarcinoma located in the nasal sinuses. In ovarian muci- 
nous adenocarcinomas, we always found co-expression of CEA 
and NCA transcripts, and occasionally BGP mRNA. CEA- 
related transcripts were also found in some serous, endometri- 
oid and clear-cell ovarian carcinomas. CEA, NCA and BGP 
transcripts were present in endometrial carcinomas of the 
uterus and cervical carcinomas, whereas uterine leiomyomas 
were completely negative. No transcripts were found from 
CGM I, CGM6, CGM7 or from PSG genes in any of the tumors 
tested. The PCR data were compared with immunohistochemi- 
cal investigations of ovarian tumors at the protein level using 
CEA (26/3/ I3)-, NCA-50/90 (9A6FR) and NCA-95 (80H3)- 
specific monoclonal antibodies. 
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Tumor markers are usually defined as molecules produced 
by malignancies, whose presence or altered serum concentra- 
tion, as compared with normal values, gives an indication that 
a tumor exists. Carcinoembryonic antigen (CEA) is a widely 
used human tumor marker for a variety of carcinomas (re- 
viewed in Shively and Beatty, 1985). It is a membrane-bound 
glycoprotein that is also released into the blood and other body 
fluids. For this reason, not only are post-operative CEA serum 
levels a useful parameter for monitoring recurrent tumors, but 
the presence of CEA on the surface of tumor cells also offers 
the possibility of localizing tumors with CEA-specific, radiola- 
belled antibodies and targetting in immunotherapy. CEA is 
not a tumor-specific antigen, but it has only a low steady-state 
concentration in normal tissues. 
CEA is a member of a family of glycoproteins with variable 
expression patterns. CEA-related antigens are present in 
different normal tissues: for example, non-specific cross- 
reacting antigen (NCA) is found in granulocytes, while biliary 
glycoprotein (BGP) is present in bile (reviewed in Thompson 
et al., 1991). The protein backbone, as determined by protein 
microsequencing or as derived through molecular cloning, 
reveals high sequence similarity among individual members of 
the CEA family. A gene family exists, comprising at least 22 
genes (Khan et al., 1992) closely clustered on the long arm of 
chromosome 19 (Thompson et al., 1991). Sequence compari- 
sons allow a division into 2 main sub-groups, one encoding the 
classical CEA and cross-reacting antigens, the other the 
pregnancy-specific glycoproteins (PSGs) expressed in increas- 
ing amounts by the placenta during pregnancy. 
A major problem in studying the expression of CEA-related 
antigens at the protein level has been the lack of well- 
characterized antibodies that are specific for individual anti- 
gen species. Through molecular cloning and the creation of 
stable transfectants expressing individual members of the CEA 
family, panels of monoclonal antibodies (MAbs) have been 
tested using FACscan analyses to better define their specifici- 
ties (Daniel et al., 1993). The mass of sequence data produced 
in the last few years has also made it possible to study the 
expression patterns of individual members at mRNA level. 
Transcripts have been found by cDNA cloning studies and 
DNA/RNA hybridization (Northern) analyses for 17 CEA- 
related genes (reviewed in Thompson et al., 1991; Khan et al., 
1992), yet the assignment of each CEA-related antigen to a 
specific gene remains difficult. Nevertheless, transcripts have 
been assigned to CEA (Oikawa et al., 1987), NCA-50/90 
(Neumaier et al., 1988), NCA-95 (Berling ef al., 1990) and BGP 
(Hinoda et al., 1988). 
Although the CEA cross-reacting antigens are expressed in 
various normal tissues, they may also be useful as tumor 
markers. For example, PSGs have been used as markers for 
choriocarcinomas (Sakuragi, 1982). A 3.9-kb transcript for 
BGP has been reported not only in normal human hepatocytes 
but also in 16/21 hepatocellular carcinomas (Hinoda et al., 
1990). NCA but not CEA transcripts are more prevalent in 
benign adenomas and colonic carcinomas than in adjacent 
normal mucosa, indicating the potential use of NCA as a 
marker for progression towards malignancy of colonic tumors 
(Chi et al., 1991). In contrast, CEA and BGP transcripts have 
recently been reported to be more prevalent in certain lung 
tumors than in corresponding normal tissues (Kim et al., 1992). 
We here examine in more detail the potential usefulness of 
individual members of the CEA family as tumor markers and 
attempt to determine their expression patterns more exactly. 
It is usually necessary to use labelled DNA fragments to 
visualize transcripts using the DNA/RNA hybridization 
method. However, due to their high sequence similarities, it is 
not possible to differentiate all CEA-related transcripts with 
DNA fragment probes. On the basis of existing sequence data, 
we describe here the design and testing of oligonucleotide 
primer pairs to identify specific CEA-related transcripts in 
human tumors, using the reverse transcriptase/polymerase 
chain reaction (RT/PCR). The presence or absence of given 
transcripts has been correlated with the presence or absence of 
corresponding antigens as indicated by MAbs specific for 
CEA, NCA-50/90 and NCA-95. 
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MATERIAL AND METHODS 
Oligonucleotide primers 
Sequence comparisons of individual CEA-gene-family mem- 
bers were carried out using published sequences to design 
oligonucleotides specific for CEA, NCA, BGP, CGM6, CGM1, 
CGM7 and for PSG1-PSG15 (Table I). A set of oligonucleo- 
tide primers was also synthesized for amplification of all known 
CEA-gene-family members. In order to achieve this, the 
program “Primer” was applied (Lucas et al., 1991). This 
program was developed in our group for the comparison and 
identification of specific nucleotide sequences from gene 
families. 
Source of cDNA clones 
A full-length CEA cDNA clone was constructed (Pdegrin et 
al., 1992), sub-cloned into a Bluescript M13+KS vector (Strata- 
gene, La Jolla, CA) and linearized prior to PCR analysis by 
Hind111 digestion. A 2-kb EcoRI fragment of the cDNA clone 
pNCAl (Neumaier et al., 1988) containing the coding region of 
NCA and a BamHI/EcoRI fragment from the partial BGP 
cDNA clone 18 (Hinoda et al., 198S), both kindly made 
available by Dr. J. Shively (Beckman Research Institute, 
Duarte, CA) were also used for primer specificity testing. For 
CGM6, a full-length cDNA clone in the Bluescript vector 
(Berling et al., 1990) was linearized using EcoRI, as was the 
PSG3 cDNA clone pSP-li (Rooney et al., 1988), which was a 
kind gift from Dr. N. Hardman (Ciba-Geigy, Basel, Switzer- 
land). A CGM7 cDNA clone which was provided by Dr. M. 
Kuroki (Fukuoka, Japan) and a cDNA clone containing the 
complete coding region of CGMla (Nagel et al., 1993) were 
also used for primer testing. 
Tumor source, RNA extraction and polymerase-chain-reaction 
conditions 
The tumors located in the brain and relevant clinical data 
were kindly provided by Dr. Seeger (Department of Neurosur- 
gery, University Hospital, Freiburg, Germany). The gynecolog- 
ical tumors and clinical data were from Dr. T. Bauknecht 
(Department of Gynecology, University Hospital, Freiburg, 
Germany) and Dr. J. Arsenau (Department of Pathology, 
Royal Victoria Hospital, Montreal, Canada). Tumor material 
was quick-frozen in liquid nitrogen and stored at -70°C prior 
to RNA isolation from 0.5 to 1 g tumor tissue, using the acid 
phenol extraction method described by Chomczynski and 
Sacchi (1987) or the guanidinium-isothiocyanate extraction 
procedure (Sambrook et al., 1989). Tissues were first ground 
under liquid nitrogen with a pestle and mortar and finely 
homogenized in extraction buffer using a tight-fitting glass/ 
Teflon homogenizer. 
Reverse transcription and polymerase chain reactions were 
slightly modified after Sambrook et al. (1989), as described in 
Lucas et al. (1991). For the reverse transcription step, either 25 
pmole of the selected 3‘ oligonucleotide or later 50 pmole of a 
random hexamer mixture (Pharmacia, Uppsala, Sweden) were 
used to prime first-strand DNA synthesis from 200 ng or 1 pg 
of total RNA. The optimized system utilized 50 pmole of 
random hexamer and 1 pg of total RNA for reverse transcrip- 
tion. The specific oligonucleotides (50 pmole each) were 
added after the reverse-transcription step, and 30 amplifica- 
tion cycles were applied using optimal annealing temperatures 
(Table I) for the given primer sets (15 sec/step). 
Prior to testing for the presence of CEA-related transcripts, 
the integrity of the RNA extracted from various tumors was 
determined. This control was to rule out false negative results 
where the RNA may be degraded, or reverse transcription 
and/or DNA amplification inhibited due to the presence of 
impurities. It was achieved by PCR using a primer set to 
amplify p-actin transcripts. This was tested both with and 
without reverse transcriptase, so as to avoid false positive 
signals due to contaminating DNA in the preparations. It is 
known that a large number of processed p-actin pseudogenes 
exists (Ng et al., 1985), and, in the absence of the reverse 
transcription step, positive signals of the same size as from the 
mRNA reveal DNA contamination. However, even in the 
presence of contamination, differences in signal strength or 
banding pattern can still be used to confirm RNA integrity. As 
no intronless pseudogenes have so far been discovered for the 
CEA-gene family, DNA contamination should not create 
problems with the PCR. In the search for another ubiquitously 
TABLE I - PRIMER SETS FOR SPECIFIC AMPLIFICATION OF CEA-RELATED AND CONTROL TRANSCRIPTS BY RTIPCR 
Transcripts Primer pairs Sequences Exon Reference 
PCRpactinS’ 5’-ACGGCTGCITCCAGCTCCTC-3’ 3 685 =j 706 64 Ponte et al ,  1984; 
@-actin PCRpactin3’ 5’-AGCCATGCCAATCXCATCITGT-3‘ 3’-UTR 1188 =) 1209 Ng et aZ., 1985 
PCRAF3LlB5’ S’-ATGGGGCAGCAGCCTGGAAA-3’ l b  1 * 20 407 6o Bernardsetal., 1987; 
PCRABL3’ 5’-GTGATGTAGTTGCITGGGAC-3‘ internal 388 - 407 Fainstein et a/., c-abl 
All CEA- PCRCEAall5’ S ’ - G G C A G A G G C K C T G C 3 ’  5’/L 44 =) 62 56 listed in Thompson 
1989 
family PCRCEAall3’ 5‘-TCAGCAGGGATGCA?TGG-3‘ LIN 308 325 282 etal., 1991 
transcriuts 
CEA 
NCA 
BGP 
CGM6 
CGMl 
CGM7 
All PSG 
transcripts 
PCRCEA-5’ 
PCRCEA-3‘ 
PCRNCA-5’ 
PCRNCA-3’ 
PCRBGP-5‘ 
PCRBGP-3’ 
PCRCGM6-5’ 
PCRCGM6-3’ 
PCRCGMl-5’ 
PCRCGMl-3’ 
PCRCEAall5’ 
PCWSGal15’ 
PCRPSGall3‘ 
PCRCGM7-3’ 
5 ’-CCATGGAGTCTCCCXCG-3’ 
5 ‘-GTAGCITGCTGTGTCATITC-3’ 
5 ’-‘ITCITCXACTCGCCCACAAC-3’ 
5’-G’ITC(JITITGACGCl’GAGTA-3 ’ 
5 ‘-AGGTGAAGACAGGGCCAGC-’3‘ 
s~-ATG~ccA-’ITGAT~GCCAG-~~ 
5 ’-ATCTCAGCCCCITCCXGCAG-3’ 
S’-CAG’ITGTAGCCACGAGGGTC3 ’ 
5 ’-GGAA’ITCCTGGAGCCCAGGCTCTIT-3‘ 
5’-CTGTCGAGGTCTCCACA-3‘ 3 
5 ’-GGCAGAGGCXCCTGCTCAC-3 ’ 
5 ‘-CAG’ITGCITGGTCAGAGTCG-3 ‘ 
5 ’-AGTITCTGGATCC?AGC%?f-3’ 
5’-GATGTAATGTAATGGTAGAGG-3’ 
5‘/L 
A1 
LIN 
A 
5I.L 
B1 
5’/L 
N 
5’IL 
l’-UTR 
5’1L 
N 
5’iL 
N 
-2 15 
620 * 639 
152 =) 171 
606 =) 625 
811 =z 830 
10 =) 29 
181 =) 200 
-56 -35 
920 =$ 936 
44 - 62 
387 =) 406 
222 * 242 
-29 =) -11 
-56 * -38 
641 
474 
859 
191 
992 
363 
298 
56 
58 
56 
64 
54 
58 
56 
Oikawa et af, 1987 
Neumaier et al., 1988 
Hinoda et aZ., 1988 
Berling et aZ., 1990 
Kuroki et a/., 1991 
Kuroki et aZ., 1991 
listed in Thompson 
etaZ., 1991 
~ 
The positions of the CEAall and PSGall primer sets are based on the sequences for CEA (Oikawa et a/., 1987) and PSG3 (Rooney et 
aZ., 1988), respectively. The primer PCRCGM1-5’ has an EcoRI linker at the 5’-end (bold print indicates extended sequence not found 
in CGMl). For exon nomenclature of CEA-gene family, see Thompson et al. (1991). nc, nucleotides; bp, base pairs. 
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expressed control mRNA, where no processed pseudogenes 
exist, we synthesized a primer set (Table I) for the amplifica- 
tion of the Ib transcripts for the proto-oncogene c-abl (Ber- 
nards et al., 1987). 
For each primer set, positive and negative controls were 
included in the RT/PCR reaction. As a negative control, water 
instead of RNA was used in all cases. For the CEAall, CEA 
and NCA sets, we initially used RNA from a human colonic 
tumor and later from an ovarian mucinous tumor as positive 
controls. Total RNA from leukocytes of a chronic myeloid 
leukemia patient and later RNA from transfectants expressing 
the respective CEA-family members were the positive controls 
for the BGP, CGM1, CGM6 and CGM7 primer sets. Alterna- 
tively, for the BGP set, RNA from the human adenocarcinoma 
cell line HT29 was also used. The positive control for the 
PSGall primer set was total RNA from a term placenta. 
Transfer of DNA and oligonucleotide hybridization 
After size separation of DNA fragments on agarose gels, 
alkaline transfer to Biodyne B membranes (PALL, Dreieich, 
Germany) was carried out according to Chomczynski and 
Qasba (1984). The following oligonucleotides were synthe- 
sized as specific internal probes to unequivocally identify each 
amplification product: 
CEA/PSGall 5 ' - C C T C A C l T Y T M A M C G - 3 '  (ma.  1 mismatch) 
CEA-specific S'-GGGATGCACCATCTGTGGG-3' ( z 3 mismatches) 
NCA-specific 5'-GCTGTAACCAATACGAT-3' ( z 3 mismatches) 
BGP-specific 5'-CATGGATTCAGTAGTGAGCTGG-3' ( Z 2 mismatches) 
CGM6-specific 5'-GATGCGCCATCTGCAGGAAG-3' ( 2 2 mismatches) 
CGM1-specific 5'-TGCGACACTGAGCGGCATGGAT-3' ( 2 3 mismatches) 
CGM7-specific 5'-CCCTTGTGCCMTAATA-3' ( z 5 mismatches) 
PSGall-specific 5'-TAATGTAATGGTAGAGGTC-3' ( t 5 mismatches) 
The sequence source for each oligonucleotide is as listed in 
Table I. The minima1 number of mismatches to other members 
of the CEA gene family are indicated in brackets. The 
CEA/PSGall oligonucleotide was designed to hybridize with 
all family members with maximally 1 mismatch. For the 
PSGall-specific probe, maximally 2 mismatches were found to 
all PSG sub-group members. Oligonucleotides were 5'-end- 
labelled, hybridized (Sambrook et al., 1989) and washed to 
approximately 4°C below their theoretical melting tempera- 
tures, as calculated according to Lathe (1985), in 6x SSPE (1 x 
SSPE is 0.18 M NaCl, 10 mM Na-phosphate, pH 7.4, and 1 mM 
EDTA), 0.1% SDS. The maximal wash temperatures for the 
CEAIPSGall- and PSGall-specific oligonucleotides took into 
account a maximum of 1 or 2 mismatches respectively. 
Immunohistochemistry 
Frozen tumor material was embedded in Tissue Tek Freeze 
medium (Reichert-Jung, Vienna, Austria) and sectioned on a 
cryomicrotome (Model 2700 Frigocut, Reichert-Jung). Sec- 
tions of 7 to 10 pm were stored on poly (L-lysine) coated slides 
at -7O"C, and parallel sections were stained with hemalaud 
eosin for identification of tissue structure. Prior to freezing, 
the sections were dried under vacuum at room temperature or 
30°C for 1 to 2 hr and fixed for 10 min in acetone. Thawed 
sections were air-dried and re-hydrated in PBS. Endogenous 
peroxidase activity was blocked by incubation in 0.3% HzOz in 
methanol for 30 min. Pre-incubation with 3% ovalbumin, 
Grade I1 (Sigma, St. Louis, MO) was carried out before the 
antibody incubations were made. Monoclonal antibodies 
(Daniel et al., 1993) were used to differentiate CEA (26/3/13), 
NCA-50/90 (9A6FR) and NCA-95 (80H3) using the avidin- 
biotin (ABC) procedure and a Vectastain kit (Vector, Burlin- 
game, CA). The first antibodies were diluted to a concentra- 
tion of 5 pg/ml PBS (137 mM NaCl, 2.7 mM KCl, 8.1 mM 
Na2HP04, 1.8 mM KH2P04, pH 7.4) for incubation. The rabbit 
anti-mouse IgG bridge antibodies were used at a dilution of 15 
pg/mI PBS and the avidin-biotin complex was diluted 1:125 in 
PBS. Counterstaining was carried out with hemalaun. Positive 
controls for CEA and NCA-50/90 were colonic tumor, or 
normal colon sections. For NCA-95, the positive control was a 
human blood smear. As negative control, the first antibody was 
either omitted from the buffer or replaced by mouse IgG. The 
specificity of the antibodies has been tested elsewhere in 
FACscan analyses, using stable transfectants expressing CEA, 
NCA-50/90, CGM6 (NCA-95), BGP, CGMl and CGM7 
(Daniel et al., 1993). 
RESULTS 
Development of a PCR system for identification of transcripts 
derived from CEA-gene-family members 
In order to synthesize specific or common oligonucleotide 
primer sets it was necessary to compare all known CEA-gene- 
family DNA sequences. To be certain that the amplification 
products originated from tumor RNA and not from contami- 
nating genomic DNA, the 5' and 3' oligonucleotides were 
chosen from different exons (Table I). 
The different primer sets were then tested and their anneal- 
ing temperatures optimized for their specificities against vari- 
ous CEA-related cDNAs (Fig. 1) .  One primer set 
(PCRCEAall5'/PCRCEAall3') was designed to amplify mRNA 
of all CEA-gene-family members and an amplification product 
of the expected size was found for all cDNA clones tested (Fig. 
la ) .  In all cases, amplification fragments of the expected sizes 
were seen (Table I). Despite theoretical specificity of the 
primer sets designed to amplify only individual members of the 
CEA-gene family, when tested against all cDNA clones, some 
cross-amplification with products of the same or different sizes 
was found Fig. 1, c;p. However, higher specificity was achieved 
by transferring the amplification products to nylon membranes 
and by hybridization with internal oligonucleotides specific for 
each product with their respective cDNA templates. 
The c-abl primer set as a control for the integrity of the RNA 
was tested against total genomic DNA where no amplification 
signals were seen (data not shown) and optimized for amplifi- 
cation of total RNA extracts. In order to get visible signals for 
the c-abl transcript, 1 pg of total RNA per PCR was needed. 
For determination of the optimal amounts of total RNA 
needed to give visible signals in the PCR reaction for CEA- 
related transcripts, variable amounts of RNA from a human 
colon adenocarcinoma were tested. Although signals were still 
visible with 1 to 10 ng RNA for CEA and NCA, we used 200 ng 
total RNA for the first screenings. However, after comparing 
the results gained with the immunohistochemical staining 
patterns from the same tumors, it became obvious that the 
latter showed greater sensitivity. For this reason, and for 
uniformity with the c-abl control, we then increased the 
amount of total RNA to 1 pg/reaction. 
Once the PCR conditions had been optimized, total RNA 
from selected tumors expected to be either positive (various 
carcinomas) or negative (different brain tumors), was tested 
for the presence of CEA-related transcripts (Table 11). In 
order to avoid screening each RNA with all primer sets, after 
determining the integrity of the RNA, a primer set was used 
which should amplify all CEA-related transcripts (Fig. la). 
Those RNAs that were negative with this primer set were not 
further tested with specific oligonucleotides. Three carcinomas 
revealed expression products of the expected size for CEA and 
NCA: a squamous carcinoma of the lung, an adenocarcinoma 
of the pancreas (these were included as positive controls) and 
an adenocarcinoma located in the nasal sinuses. No transcripts 
were found for BGP, CGM6 or the PSG sub-group. CGMl and 
CGM7 transcripts were not determined. As expected, none of 
the neuroepithelial (n = 4) or the mesenchymal brain tumors 
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FIGURE 1 - Specificity control of primer sets designed to amplify transcripts from individual CEA-gene-family members. PCR 
amplification was carried out using cDNA clones as templates from individual members of the CEA-gene family (listed above). A HincII 
digest of bacteriophage +X174T was used as a size marker. The following oligonucleotide primer sets (listed in Table I) were used: a,  
PCRCEAall; b, PCRCEA, c, PCRNCA, d, PCRBGP; e,  PCRCGM6; f, PCRCGM1; g,  PCRCGM7; h, PCRPSGall. Ethidium-bromide 
staining of the DNA after separation on a 1.8% agarose gel is shown in the upper section and the hybridization results in the lower sec- 
tion of each sub-figure, using the following 5’-end-labeled, internal oligonucleotides: u, CEA/PSGall; b, CEA-specific; c, NCA-specific; 
d ,  BGP-specific; e ,  CGM6-specific;f, CGM1-specific; g,  CGM7-specific; h, PSGall-specific. 
(n = 6) tested contained transcripts for any CEA-gene-family 
member (Table 11). 
Identijication of CEA-related transcripts in gynecological tumors 
A larger-scale RT/PCR-screening was carried out on 63 
different gynecological tumors (Fig. 2; Table 111). The integrity 
of the RNA was first tested using the p-actin primer set, with 
and without the reverse transcription step. In some cases, 
DNA contamination revealed amplification products with and 
without reverse transcription (Fig. 2d: colon-tumor metasta- 
sis). However, the larger fragment representing the active 
p-actin gene with intervening intron sequences was visible only 
in the absence of reverse transcription. As this fragment 
usually disappeared after inclusion of reverse transcription, 
intact R N A  must also be  present in such R N A  samples. 
Parallel controls with the c-abl primer set confirmed these 
results (data not shown). In cases where the R N A  was intact, 
the expression of CEA and CEA-related transcripts was 
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TABLE I1 - DETECTION OF CEA-GENE-FAMILY TRANSCRIPTS IN SELECTED TUMORS USING AN RTIPCR ASSAY 
1 pg total RNA c-ablip-actin CEAall CEA NCA BGP CGM6 CGMl CGM7 PSGall 
Epithelial tumors 
- - - - - Breast carcinomas 212 012 - 
111 1/1 111 011 0/1 nd nd 01 1 
1/1 111 1/1 1/1 0/1 o/ 1 nd dn 0/1 
Pancreas adenocarcinoma 
Lung squamous carcinoma 
Neuro-epithelial tumors 
- - - - - - - 
- - - - - - - 
Astrocytomas 212 012 
Oligodendroglioma 111 01 1 
Glioblastoma multiforma 1/1 o/ 1 - - - - - - - 
Intracranial epithelial tumor 
Mesenchymal brain tumors 1/1 1/1 111 111 Oil Oil nd nd 0/1 
Nasal sinus adenocarcinoma 
Meningeomas 414 014 
Hemangioblastoma 1/1 011 
Non-Hodgkin lymphoma 111 Oil 
Lung squamous carcinoma 111 011 
Ovarian carcinoma 1/1 011 
- - - - - - - 
- - - - - - - 
- - - - - - - 
Metastases in brain 
- - - - - - - 
- - - - - - - 
nd, not determined 
FIGURE 2 - Identification of CEA-related transcripts in ovarian tumors. RNA isolated from different tumors was reverse transcribed 
and PCR-amplified using the following oligonucleotide primer sets: a, PCRCEA, b, PCRNCA, c, PCRBGP; d ,  PCRpactin, to specifically 
amplify CEA, NCA, BGP and p-actin transcripts respectively. Examples are shown from different tumor types (listed above) along with 
positive controls from respective cDNA clones. The upper part of the figure shows ethidium-bromide staining of DNA gels; the lower 
part shows hybridization results with the following internal oligonucleotide probes: a,  CEA-specific; b, NCA-specific; c, BGP-specific. In 
d ,  the upper part of the figure is with reverse transcription and the lower part is without this step. 
investigated. As seen in Table 111, co-expression of CEA, NCA 
and occasionally BGP transcripts, but of no other CEA-gene- 
family member, was found in the mucinous ovarian carcinomas 
(n = lo),  whereas CEA-related transcripts were found only in 
4112 serous, 417 endometrioid and 217 clear-cell ovarian 
carcinomas. From 200 ng total RNA, benign leiomyomas of the 
uterus revealed no CEA-related transcripts (n = 7), whereas 
some endometrial adenocarcinomas as well as carcinomas of 
the cervix expressed transcripts for CEA (2/6), NCA (2/6) and 
BGP (2/6). For unequivocal identification of the different 
amplification products, the fragments were transferred to 
nylon membrane and hybridized at high stringency with 
transcript-specific oligonucleotides (Fig. 2a-c). Although the 
lower hybridization signal seen in Figure 2c corresponds in size 
with the cross-amplification product seen with this BGP 
primer set in the ethidium-bromide-stained gel using the PSG3 
cDNA as a control (Fig. Id ) ,  it does not represent a PSG, since 
the same tumours as shown in Figure 2c were negative when 
tested with the PSGall primer set (data not shown). None of 
the tumors examined revealed the presence of transcripts for 
CGM1, CGM6, CGM7 or any PSG-sub-family member in the 
conditions used (data not shown). 
Expression of CEA, NCA-50I90 and NCA-95 in gynecological 
tumors using spec@ MAbs 
Apart from the internal positive and negative controls, the 
efficacy of the PCR system was tested at the antigen level using 
specific MAbs in standard immunohistochemical studies to 
differentiate CEA (Mab 26/3/13) ,  NCA-50/90 (Mab 9A6FR) 
and NCA-95 (Mab 80H3). A typical staining pattern of these 3 
Mabs is shown on serial sections of an ovarian mucinous 
carcinoma in Figure 3. The CEA- (Fig. 3a)  and NCA50-90- 
(Fig. 3b) specific antibodies both reveal positive staining of 
tumor cells, whereas NCA-95 is present only in granulocytes 
(Fig. 3c) and not in tumor cells in this example. The negative 
control reveals no unspecific background staining (Fig. 3 4 .  
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TABLE I11 - DETECTION OF CEA-GENE-FAMILY TRANSCRIPTS IN GYNECOLOGICAL TUMORS USING AN RTIPCR ASSAY 
c-abl/ 
B-actin 
Ovarian tumors (1 pg total RNA) 
Benign tumors 
Malignant tumors 
Carcinomas 
Cystoma 111 
Serous 12116 
Mucinous 10/10 
Endometrioid 7/10 
Clear-cell 718 
Sarcoma 111 
Teratomas 212 
Colon carcinomas 313 
Stomach carcinoma 111 
Breast carcinoma 111 
Leiomyomas 717 
Metastases in ovary 
Uterine tumors (200 ng total RNA) 
Benign tumors 
Malignant tumors 
Endometrial 
Cervical tumors 1200 ng total RNA) 
616 adenocarcinomas 
v 
Carcinomas' ' 313 
Other tumors (200 ng total RNA) 
111 Vulvar intra-epithelial 
Fallouian-tube carcinoma 111 
neoplasia 
CEAall CEA NCA BGP CGM6 CGMl CGM7 PSGall 
011 
4112 
10110 
417 
217 
01 1 
012 
213 
111 
111 
017 
416 
213 
111 
011 
014 014 
0110 0110 
014 014 
012 012 - - 
- - 
014 014 
012 012 
01 1 01 1 
- - 
The total results of the immunohistochemical analyses are 
compared with those from PCR studies for individual tumors 
in Table IV. The results for CEA expression at the mRNA and 
the antigen level correlate well in 17 from 19 ovarian tumors 
analyzed. For NCA-50/90, the tumors positive at the mRNA 
level were also positive at the antigen level. However, NCA- 
50/90 and NCA-95 antigen were found in 5/19 and 4/19 
tumors, respectively, that were apparently negative for the 
corresponding transcripts. In all those cases, these NCA 
species were located focally in only a few tumor cells (< 5% 
total tumor cells) and/or were present within granulocytes 
(Fig. 3c) in areas of inflammation or in non-identifiable cells. 
The number of granulocytes or non-identifiable cells stained 
was often equal to or greater than the number of positive 
tumor cells. 
DISCUSSION 
Using a computer program specifically written for this 
purpose (Lucas et al., 1991), we have synthesized and tested 
oligonucleotide primer sets against individual CEA-related 
cDNA clones that specifically amplify CEA, NCA, CGM6 
(NCA-95), BGP, CGM1, CGM7 transcripts and a set that will 
amplify only members of the PSG sub-group. For other 
members of the CEA-gene family (CGM2, CGMS, 9, 10 and 
l l ) ,  no transcripts have so far been described. Furthermore, 
sequence analyses indicate that these members, apart from 
CGM2, contain stop codons and apparently represent pseudo- 
genes (Khan et al., 1992). In future, the possibility of analyzing 
the expression of different splice products from individual 
genes, e.g., BGP or individual PSGs (Thompson et al., 1991), 
may also be taken into consideration in the design of new 
oligonucleotide primers. Furthermore, we are presently devel- 
oping a CGM2-specific primer set in the search for transcripts 
from this gene. 
The results gained in the analysis of selected tumors located 
in the brain revealed no CEA-related transcripts in neuro- 
epithelial tumors nor in mesenchymal tumors. On the other 
hand, a poorly differentiated adenocarcinoma, which repre- 
sents a primary nasal-sinus tumor, was shown to co-express 
CEA and NCA transcripts. These data support immunohisto- 
chemical studies carried out by Ang et al. (1990), who were 
unable to find CEA in 19 different brain primary tumors, 
whereas 6 brain metastases of primary tumors in the gastroin- 
testinal tract were positive. Our results indicate that the 
sensitivity level of the RT/PCR is acceptable, in that the 
expected positivity and negativity based on published immuno- 
histochemical data is reproduced. 
Co-expression of NCA and CEA transcripts in ovarian 
mucinous adenocarcinomas was confirmed using MAbs spe- 
cific against CEA and NCA-50/90. Other immunohistochemi- 
cal investigations into the expression of CEA and NCA in 
ovarian tumors correlate well with our data (Motoyama et al., 
1990). In brief, these investigations also identified CEA and 
NCA in all ovarian mucinous tumors. CEA and NCA were also 
present in a few endometrioid and clear-cell carcinomas, but 
rarely in serous ovarian carcinomas, although only a small 
percentage of tumor cells were positive. Co-expression of CEA 
and NCA is often found in other types of adenocarcinomas, 
eg.,  colonic adenocarcinomas, as shown by DNA/RNA hybrid- 
ization analyses (Chi et al., 1991). The immunohistochemical 
staining on serial sections has often, but not always, revealed 
that the same tumor cells express both CEA and NCA. It 
appears that co-regulation of gene expression may exist in such 
cases. The genes encoding CEA and NCA are directly adjacent 
on the long arm of chromosome 19, being separated by only 
approximately 16 kb (data not shown). The coordination of 
expression of these genes could, therefore, be under the 
control of common cis-acting regulatory elements. However, in 
granulocytes, NCA but not CEA is expressed (Berling et al., 
1990), indicating that gene-specific control elements must also 
exist. Indeed, in these investigations, some of the tumor cells 
expressed CEA but not NCA, or vice versa. In a few other 
tumors, the CEAall primer set yielded amplification products, 
but the specific primer sets were all negative (Table 111). This 
suggests either amplification of unknown CEA-gene-family 
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FIGURE 3 - Identification of CEA-related antigens in an ovarian mucinous adenocarcinoma by immunohistochemical staining. Serial 
tumor cryosections were incubated with specific MAbs to identify: a ,  CEA (26/3/13); b, NCA-50/90 (9A6FR); and c, NCA-95 (80H3). In 
d, lower magnification of the same area is shown in the ne ative control without first antibody. Although serial sections were analyzed, 
the region shown for NCA-95 (c) that stains granulocytes ?see inset for stronger magnification) does not corres ond exactly with those 
for CEA and NCA, but both regions are covered in the negative control (d). Bars indicate 100 pm ( a d ) ,  50 pm k r  inset in (c). 
members, or more probably, co-expression of more than one 
known family member at low levels where individual tran- 
scripts cannot be visualized at the present sensitivity level. 
However, confirmation of such low expression levels would be 
only of academic interest. 
With 200 ng of total RNA, the sensitivity of the PCR system 
was lower than that of the immunohistochemical method, since 
in the serous, clear-cell and endometrioid ovarian carcinomas, 
as well as one mucinous carcinoma, no CEA-related tran- 
scripts were detected, The PCR conditions were then modified 
by increasing the amount of total RNA to 1 pg. Under these 
conditions, the immunochemical and PCR analyses yielded 
more comparable results for expression of CEA-gene-family 
members. However, the focal staining seen in some tumor cells 
for NCA-50/90 and NCA-95 was still not detected with the 
PCR system. Although the PCR sensitivity may easily be 
further increased, problems could then arise with amplifica- 
tion of NCA, CGM1, CGM6, CGM7 and BGP transcripts 
present in granulocytes/leukocytes (Berlinget al., 1990; Kuroki 
et al., 1991) that would lead to false positives. Indeed, the 
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TABLE IV - COMPARISON OF RTIPCR-ASSAY WITH IMMUNOHlSTOCHEMlCAL DETECTION OF 
CEA-GENE-FAMILY MEMBERS IN OVARIAN TUMORS 
Immunohistochemistry UTiPCR assay 
CEA NCA-50190 NCA-95 CEA NCA CGM6 
Tumor 
Mucinous 
Mucinous 
Mucinous 
Mucinous 
Mucinous 
Mucinous 
Serous 
Serous 
Serous 
Serous 
Serous 
Endometrioid 
Endometrioid 
Endometrioid 
Endometrioid 
Clear cell 
Clear cell 
Clear cell 
Clear cell 
(+) indicates only a weak signal in the RT/PCR assay or only 5 5% of the tumor cells stained 
positively. 
number of granulocytes/leukocytes visualized in those tumors 
showing positivity only after immunohistochemical staining 
was often equal to  or  greater than the number of NCA-50/90- 
or NCA-95-positive tumor cells. However, in the present PCR 
conditions, this has not been a problem; and in those tumors 
where NCA transcripts were found, immunohistochemical 
analysis confirmed that the tumor cells themselves were 
NCA-50/90- positive. Even without the latter control, where 
NCA products are found in the absence of amplification 
products for CGM6, as in all the tumors investigated here, it 
may be concluded that NCA is, indeed, expressed in the tumor 
cells and not in granulocytes, since steady-state CGM6 mRNA 
levels are generally higher than NCA mRNA levels in granulo- 
cytes (Berling et aL, 1990). 
In general, this RT/PCR assay provides a useful system for 
specific identification of transcripts for each CEA-related 
gene. This cannot be achieved at the antigen level for all family 
members, due to  the lack of specific antibodies for each 
species, or through DNA/RNA hybridization studies, because 
many probes will cross-hybridize or be of limited sensitivity. A 
further advantage of this PCR system is that its unlimited sen- 
sitivity makes it feasible to carry out such studies on biopsy ma- 
terial (e.g., fine-needle aspirates) where the amounts of tumor 
tissue available for analysis are very small. In such cases, higher 
sensitivity may be  attained by increasing the number of cycles 
rather than the R N A  amounts, which will also be limiting. 
The preliminary studies presented here indicate that not 
only CEA, but also NCA, may be a useful tumor marker for 
ovarian mucinous adenocarcinomas, whereas the expression of 
other CEA-family members is more limited or  completely 
absent from the tumors investigated so far. These analyses will 
be  continued and further optimized on other tumors in which 
expression of CEA and CEA-related antigens have been 
reported, eg., tumors of the breast, lung and pancreas, and 
trophoblastic tumors. 
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